What I would recommend is researching historical pharmaceutical IP issues with China. NP has mentioned Humira a few times, so maybe someone could look into Humira sales in China over the past 15 years. I think this is a good place to start to better understand the IP threat that a China deal POSSIBLY poses to leronlimab.